相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
M. Hofmann et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17
Rosalba Torrisi et al.
EUROPEAN JOURNAL OF CANCER (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
Lissandra Dal Lago et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+in immunohistochemical analysis
R. Merola et al.
EUROPEAN JOURNAL OF CANCER (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast - A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
E Downs-Kelly et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice
Y Ma et al.
CLINICAL CANCER RESEARCH (2005)
Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
I Vanden Bempt et al.
HISTOPATHOLOGY (2005)
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
M Salido et al.
BREAST CANCER RESEARCH (2005)
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
P Lal et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2003)
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma
AD Watters et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience
S Paik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
PC Roche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
AD Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin
JA Carlson et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
